Bioline Rx Common Stock

As of the most recent data (June 2026), BLRX shows a common stock of $74M. That compares with $72M in the prior-year period — up 2.7% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, BLRX's common stock is now $74M (was $72M) — a 2.7% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Bioline Rx is outperforming or lagging.

Tracking BLRX's common stock over time shows whether Bioline Rx is scaling, shrinking, or reshaping that part of the business. The current reading is $74M That compares with $72M in the prior-year period — up 2.7% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this common stock page, Stockcircle has Bioline Rx's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect common stock (currently $74M) with ownership activity and broader fundamentals.

Bioline Rx's common stock is $74M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.